Skip to main content

Advertisement

SpringerLink
Log in

“Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma

  • Laboratory Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the role of “melanoma inhibitory activity” (MIA) as a potential serum marker for screening and detection of metastatic uveal melanoma.

Design

Prospective, clinical study.

Material and methods

Serum samples of 305 patients with uveal melanoma were collected. Serum samples were analysed by a one-step enzyme-linked immunosorbent assay (ELISA) to quantify the MIA serum levels. All patients underwent a standardized echography of the globe to evaluate maximum tumour height and were checked for systemic metastasis of the tumour by liver enzyme tests and ultrasonography of the liver.

Results

Twenty patients (6.6%) had proven metastatic disease; eight of them developed it during follow-up. The mean serum concentration of MIA in the 285 patients without metastasis was 6.72 ng/ml, whereas the mean serum concentration of MIA in the 20 patients with metastasis was 13.03 ng/ml (P<0.001). The eight patients who developed metastatic disease during follow-up showed an MIA of 5.92 ng/ml before detection of metastasis and 12.21 ng/ml afterwards (P<0.001). MIA serum levels did neither correlate with the tumour height or to whether local therapy had been applied.

Conclusion

The elevation of MIA serum levels in patients with metastatic disease from melanoma supports its promising role as a serum marker for monitoring patients with uveal melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Albert DM, Niffeneger AS, Willson JK (1992) Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 36:429–438

    Article  PubMed  CAS  Google Scholar 

  2. Blesch A, Bosserhoff AK, Apfel R, Behl C, Heβdörfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695–5701

    PubMed  CAS  Google Scholar 

  3. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153

    PubMed  CAS  Google Scholar 

  4. Bosserhoff AK, Golob M, Buettner R, Landthaler M, Hein R (1998) MIA (“melanoma inhibitory activity”): Biologische Funktionen und klinische Relevanz beim malignen Melanom. Hautarzt 49:762–769

    Article  PubMed  CAS  Google Scholar 

  5. Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R (1999) In situ expression patterns of melanoma-inhibiting activity (MIA) in: melanomas and breast cancers. J Pathol 187:446–454

    Article  PubMed  CAS  Google Scholar 

  6. Collaborative Ocular Melanoma Study Group (COMS) (2004) Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group. Report 23. J Clin Oncology 22:2438–2444

    Article  Google Scholar 

  7. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP (1992) A review of mortality from choroidal melanoma. A meta-analysis of 5-year mortality rates following enucleation. 1966 through 1988. Arch Ophthalmol 110:245–250

    PubMed  CAS  Google Scholar 

  8. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM (1988) Epidemiological aspects of uveal melanoma. Surv Ophthalmol 32:239–251

    Article  PubMed  CAS  Google Scholar 

  9. Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85:1151–1159

    Article  PubMed  CAS  Google Scholar 

  10. Folberg R, Mehaffey M, Gardner LM, Meyer M, Rummelt V, Pe’er J (1997) The microcirculation of choroidal and ciliary body melanomas. Eye 11:227–238

    PubMed  Google Scholar 

  11. Gamel JW, McLean IW, McCurdy JB (1993) Biologic distinctions between cure and time to death in 2,892 patients with intraocular melanoma. Cancer 71:2299–2305

    Article  PubMed  CAS  Google Scholar 

  12. Goto H, Tenou T, Kudo H, Iwasaki T, Maramatsu R, Usui M, Wakamatsu K, Ito S (1998) 5-S-cysteinyldopa as a diagnostic tumor marker for uveal melanoma. Nippon Ganka Gakkai Zasshi 102:319–326

    PubMed  CAS  Google Scholar 

  13. Haritoglou C, Neubauer AS, Herzum H, Freeman WR, Mueller AJ (2002) Interobserver and intraobserver variability of measurements of uveal melanomas using standardized echography. Br J Ophthalmol 86:1390–1394

    Article  PubMed  CAS  Google Scholar 

  14. Hicks C, Foss AJE, Hungerford JL (1998) Predictive power of screening tests for metastasis in uveal melanoma. Eye 12:945–948

    PubMed  Google Scholar 

  15. Kan-Mitchell J, Liggett PE, Taylor CR, Rao N, Granada ESV, Danenberg KD, White WL, Van Eldik LJ, Horikoshi T, Danenberg PV (1993) Differential S100β expression in choroidal and skin melanomas: quantitation by the polymerase chain reaction. Investig Ophthalmol Vis Sci 34:3366–3375

    CAS  Google Scholar 

  16. Kuan AK, Jackson FI, Hanson J (1988) Multimodality detection of metastatic melanoma. J R Soc Med 81:579–582

    PubMed  CAS  Google Scholar 

  17. McLean I, Forster W, Zimmerman L (1980) Choroidal melanoma. Arch Ophthalmol 98:1298–1303

    PubMed  CAS  Google Scholar 

  18. Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8:283–298

    Article  PubMed  CAS  Google Scholar 

  19. Mooy CM, De Jong PTVM (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41:215–228

    Article  PubMed  CAS  Google Scholar 

  20. Mueller AJ, Bartsch DU, Schaller UC, Freeman WR, Kampik A (2001) Imaging the microcirculation of untreated and treated human choroidal melanomas. Ophthalmology 23:385–393

    CAS  Google Scholar 

  21. Mueller AJ, Freeman WR, Schaller UC, Kampik A, Folberg R (2002) Complex microcirculation patterns detected by confocal indocyanine green angiography predict time to growth of small choroidal melanocytic tumors. Ophthalmology 109:2207–2214

    Article  PubMed  Google Scholar 

  22. Ossoinig KC, Bigar F, Kaefring SL (1975) Malignant melanoma of the choroid and the ciliary body: differential diagnosis in clinical echography. Ultrasonography in ophthalmology, Basel, Karger 83:141–154

  23. Pach JM, Robertson DM (1986) Metastasis from untreated uveal melanomas. Arch Ophthalmol 104:1624–1625

    PubMed  CAS  Google Scholar 

  24. Rummelt V, Folberg R, Woolson RF, Hwang T, Pe’er J (1995) Relation between the microcirculation architecture and the aggressive behaviour of ciliary body melanomas. Ophthalmology 102:844–851

    PubMed  CAS  Google Scholar 

  25. Schaller UC, Mueller AJ, Bosserhoff AK, Haraida S, Löhrs U, Buettner R, Kampik A (2000) Melanoma inhibitory activity (MIA): Evaluierung eines neuen tumorassoziierten Antigens als Serummarker für uveale Melanome. Ophthalmologe 97:429–432

    Article  PubMed  CAS  Google Scholar 

  26. Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ (2002) Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 12:593–599

    Article  PubMed  CAS  Google Scholar 

  27. Terheyden P, Kämpgen E, Rünger TM, Bröcker EB, Becker JC (1998) Immunochemotherapie des metastasierenden Uveamelanoms mit Interferon-α2b, Interleukin-2 und Fotemustin: Kasuistiken und Literaturübersicht. Hautarzt 49:770–773

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are indebted to Dr. Markus Schaumberger (Department of Ophthalmology, Ludwig-Maximilians University, Munich) for helping in the statistical review of this manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Ludwig-Maximilians University, Mathildenstrasse 8, 80336, Munich, Germany

    I. W. Reiniger, U. C. Schaller, C. Haritoglou, A. Kampik & A. J. Mueller

  2. Department of Dermatology, Technical University, Biedersteinstr. 29, 80802, Munich, Germany

    R. Hein

  3. Institute of Pathology, University of Regensburg, Franz-Joseph-Strauβ-Allee 1, 93042, Regensburg, Germany

    A. K. Bosserhoff

Authors
  1. I. W. Reiniger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. C. Schaller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Haritoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. K. Bosserhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Kampik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. J. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. W. Reiniger.

Additional information

The results from this study were presented at the Annual Meeting of the German Society of Ophthalmology (102. Tagung der DOG - Deutsche Ophthalmologische Gesellschaft)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reiniger, I.W., Schaller, U.C., Haritoglou, C. et al. “Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefe's Arch Clin Exp Ophthalmo 243, 1161–1166 (2005). https://doi.org/10.1007/s00417-005-1171-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-005-1171-4

Keywords

Search

Navigation